Monday 4 October 2021

Patients treated with chemotherapy and B cell-targeting agents show impaired serological response to COVID-19 vaccination

 

A recently completed cohort study conducted in Austria and Italy on patients with haemato-oncological diseases indicates that "patients with cancer are able to develop SARS-CoV-2 specific antibodies."  The study, conducted on 595 patients being treated for haematological and solid malignant tumours, compared to 58 healthcare workers acting as controls, showed that in both cohort, "anti-S antibody levels were higher in fully vaccinated patients coparents with patients who received 1 vaccine dose." 

To read more about this study, click here. 

Source mentioned: Mair MJ, Berger JM, Berghoff AS, et al. Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. JAMA Oncology; Published online 30 September 2021. doi:10.1001/jamaoncol.2021.5437

No comments:

Post a Comment